Clinical Publications

• Li K, Chu C, Patel M, Meng M, Morgan T, Porten S. Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. Urol Oncol. 2023 Mar 1;S1078-1439(23)00009-1. doi: 10.1016/j.urolonc.2023.01.009 [Online ahead of print]

• Lotan Y, Raman JD, Konety B, Daneshmand S, Schroeck F, Shariat SF, Black P, de Lange M, Asroff S, Goldfischer E, Efros M, Chong KT, Huang E, Chua HL, Wu QH, Yeow S, Lau W, Yong J, Eng M. Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. J Urol. 2022 Dec 30:101097JU0000000000003126. doi: 10.1097/JU.0000000000003126. [open access], [medical release]

• Woldu SL, Ng CK, Loo RK, et al. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. J Urol. 2021;205(5):1387-1393. doi:10.1097/JU.0000000000001550. [pdf available]
• Chu C, Li K, Meng M, Porten S. PD63-12: Use of Cxbladder Monitor during the COVID-19 Pandemic to reduce the frequency of surveillance cystoscopy. J Urol 2021; 206(3):1142e [abstract available]

• Raman JD, Kavalieris L, Konety B, et al. The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma. J Urol. 2021;206(6):1380-1389. doi:10.1097/JU.0000000000002135. [pdf available]

• Laukhtina E, Shim SR, Mori K, et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis [published correction appears in Eur Urol Oncol. Eur Urol Oncol. 2021;4(6):927-942. doi:10.1016/j.euo.2021.10.003. [pdf available]

• Davidson P, McGeoch G, Shand B. Assessment of a clinical pathway for investigation of haematuria that reduces the need for cystoscopy. NZ Med J 2020. 133:1527 [open access]

• Koya M, Osborne S, Chemasle C, Porten S, Schuckman A, Kennedy-Smith A. An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urology. 2020; 20:12. [pdf available]

• Georgieva, MV, Wheeler, SB, Erim, D, et al. Comparison of the Harms, Advantages, and Costs Associated With Alternative Guidelines for the Evaluation of Hematuria. JAMA Intern Med. 2019; 10.1001 [abstract available]
• Davidson, PJ, McGeoch, G, Shand, B. Inclusion of a molecular marker of bladder cancer in a clinical pathway for investigation of haematuria may reduce the need for cystoscopy. NZ Med J 2019; 132:1497. [open access]

• Konety, B, Shore, N, Kader, AK, et al. Evaluation of Cxbladder and adjudication of atypical cytology and equivocal cystoscopy. Eur Urol 2019. Article In-Press [pdf available] >> Uro Today Journal Club review by Sia Daneshmand M.D., Associate Professor or Urology, Director of Urological Oncology & Director of Clinical Research at University of Southern California (USC): [video link]

• Lough T, Luo Q, O'Sullivan P, et al. Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician–Patient Real-World Clinical Data Analysis. Oncol Ther 2018. [pdf available]

• Lough T, Luo Q, Luxmanan C, et al. Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis. BMC Urol 2018;18:18. [pdf available]

• Kavalieris L, O’Sullivan PJ, Frampton C, et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 2017;197:6,1419-1426. [pdf available]
• Darling, D, Luxmanan, C, O’Sullivan, P, et al. Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma. Adv Ther 2017. doi:10.1007/s12325-017-0518-7. [pdf available]

• Lotan Y, OʼSullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017;1–8. [pdf available]

• Lotan Y, Raman JR, Shariat S, et al. The development and clinical validation of a high sensitivity urine biomarker test for the determination of recurrence in urothelial carcinoma patients. American Urological Association Annual Meeting 2016; San Diego, CA, USA. [abstract available]

• Breen V, Kasabov N, Kamat AM, et al. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets. BMC Med Res Methodol 2015;15:45. 

• Kavalieris L, O’Sullivan PJ, Suttie JM, et al. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. BMC Urol 2015;15:23. [pdf available]

• O’Sullivan P, Sharples K, Dalphin M, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 2012;188:741–7

• Holyoake A, O’Sullivan P, Pollock R, et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res 2008;14:742–9. [pdf available]

 

To request printed versions of our publications, please contact: [email protected]

Last Updated: 28 Apr 2023 09:20 am